Beth Snyder Bulik

United States

Founder and Editor at Marketing and Pharma

Featured in: Favicon

endpts.com Favicon

adage.com

fiercepharma.com Favicon

creativity-online.com Favicon

invesbrain.com Favicon

nxtmine.com Favicon

newsbreak.com Favicon

marketingandpharma.com Favicon

3blmedia.com Favicon

pharmaceuticalintelligence.com + 1 more

Articles

Bristol Myers Squibb partners with BioNTech on new cancer drug

5 days ago | emarketer.com | Beth Snyder Bulik

The news: BioNTech is partnering with Bristol Myers Squibb to develop and commercialize a new cancer drug candidate in a sought-after treatment class. What’s driving it: The deal reinforces growing interest in a new type of cancer drug that combines two existing immunotherapy approaches: PD-1/PD-L1 (like Merck’s Keytruda and Bristol Myers Squibb’s Opdivo) and VEGF (like Genentech’s Avastin).
Trump administration drops Moderna mRNA pandemic flu research

1 week ago | emarketer.com | Beth Snyder Bulik

The news: The Trump administration cancelled Moderna’s more than $760 million contract to develop mRNA-based pandemic vaccines. Zooming in: Moderna won $590 million in funding under the Biden administration in January for research on its bird flu vaccine, plus expanded clinical trials for pandemic influenza. The cancelled work includes an initial $176 million grant last July for the bird flu research.
Medtronic spins out diabetes business into D2C company

2 weeks ago | emarketer.com | Beth Snyder Bulik

The news: Medtronic is spinning off its $2.8 billion diabetes business into a standalone direct-to-consumer company for its insulin pump and continuous glucose monitor (CGM) devices. Zooming out on the diabetes tech market: Diabetes device competitors Abbott and Dexcom market CGMs while Tandem Diabetes Care and Insulet sell insulin pumps. But after the spinoff, only Medtronic will make both the insulin pumps that deliver medication and the CGMs that monitor blood sugar changes.
Pharma companies face drug pricing and ad tax regulations by Trump administration and Congress

2 weeks ago | emarketer.com | Beth Snyder Bulik

The news: The Trump administration added new details to its plan to lower US prescription drug costs by matching global prices, as a bipartisan Congressional effort for similar legislation gets underway.
Biotech and pharma consider moving early drug trials outside US

3 weeks ago | emarketer.com | Beth Snyder Bulik

The news: Biotech and pharma companies are considering moving early-stage clinical trials out of the US in response to the Trump administration's health funding cuts. Concerns over slowed drug development have some companies considering “Europe first” experimental testing, per Reuters. Other biotechs are exploring the UK and Australia for early-stage studies, per Endpoints News.
Prescription drug injectable options are increasing consumer convenience and access

3 weeks ago | emarketer.com | Beth Snyder Bulik

The trend: Amneal Pharmaceuticals' FDA approval for an at-home auto injector migraine treatment is the latest in a growing number of prescription drug injectables for consumer use at home or on the go. Amneal’s medication Brekiya treats acute onset of migraine as an alternative for patients who don’t respond well to oral treatments. Driving the trend: GLP-1 injectable drugs for weight loss and type 2 diabetes are boosting the use of at-home injectable medications.
FDA takes aggressive AI stance to speed up drug reviews

3 weeks ago | emarketer.com | Beth Snyder Bulik

The news: The FDA is rolling out generative AI (genAI) for drug reviewers with agencywide use set for the end of June. FDA commissioner Marty Makary attributed the quick rollout to the recent success of an AI pilot for scientific reviewers. Driving the news: The new genAI review help comes amid industry predictions that massive layoffs at the FDA—3,500 employees in April—will slow down the agency’s review and approval of new prescription drugs.
Gilead boosts US manufacturing amid Trump administration tariff, HIV healthcare challenges

1 month ago | emarketer.com | Beth Snyder Bulik

The news: Gilead Sciences is investing $11 billion in new US manufacturing and R&D, adding to its already planned $21 billion over the next five years. Driving the news: Gilead joins a group of pharma companies pledging more US manufacturing under pressure from the Trump administration to build domestically amid tariff threats. In April, Roche committed $50 billion in new US manufacturing and R&D over five years, and Novartis pledged $23 billion at 10 facilities over five years.
AstraZeneca 'unfolds' first Truqap campaign for metastatic breast cancer

1 month ago | marketingandpharma.com | Beth Snyder Bulik

From new mechanisms of action like antibody-drug conjugates (ADCs) to novel drug combinations, the treatment options for metastatic breast cancer are increasing—and so is the need for patient education. The jargon around the newer therapies that target certain cancer cell characteristics or that work on specific genetic mutations can be confusing. And while patients don’t need physician-level knowledge, AstraZeneca wants people to be comfortable advocating for themselves.
Life in La La land: Pharma and health care agency GSW LA embraces Hollywood ethos

1 month ago | marketingandpharma.com | Beth Snyder Bulik

The GSW ad agency in Los Angeles is taking a page from its movie-making neighbors and using storytelling and entertainment to shake up traditional pharma advertising. It’s adopted an agency-wide mantra “Wonder More” and a mindset to be curious, restless and dig deeper on details to uncover what might be different or unexpected, agency executives said. Like a recent campaign it created for BridgeBio’s cardiovascular drug Attruby starring actor Morgan Freeman.